Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke
Update on adjuvant treatment of HER2-positive breast cancer

Authors

  • Erika Matos Onkološki inštitut, Ljubljana

Keywords:

supplementary treatment, HER2-positive breast cancer, breast cancer, HER2, adjuvant treatment

Abstract

Ni abstrakta.


Abstract (Eng)

Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer.

Published

2008-06-15

How to Cite

Matos, E. (2008). Update on adjuvant treatment of HER2-positive breast cancer. Onkologija : Slovenian Journal of Oncology, 12(1), 57–60. Retrieved from https://revijaonkologija.si/Onkologija/article/view/391

Issue

Section

Review Article